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Abstract
MicroRNAs (miRNAs) are small non-coding RNA transcripts that affect various cellular pathways by serving as
regulators of gene expression at the translational and transcriptional level. Nuclear receptors (NRs) are ligand-
activated transcription factors that regulate gene transcription by binding to the promoter region or by interacting
with other transcription factors. NRs can regulate miRNA expression either at the transcriptional level, or through
posttranscriptional maturation by interacting with miRNA processing factors. This review will summarize recent
advances in knowledge of the modulation of miRNA expression by NRs. Increased understanding of the molecular
basis of miRNA expression may enable new therapeutic interventions that modulate miRNA activities through
NR-mediated signaling.
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Introduction
The binding of microRNA (miRNA, or miR) to the 3’-
untranslated region of target mRNAs causes transcript
degradation or interferes with translation initiation. This
posttranscriptional inhibitory mechanism is of critical
importance in fundamental cell processes, including
development [1], proliferation [2], survival and death.
During the past decade, much effort has been focused on
elucidating the mechanism of miRNA target gene regula-
tion, however, relatively little is known about the regula-
tion of miRNA genes themselves [3]. A number of large-
scale expression profiling studies have shown that the
expression of miRNAs is dysregulated under various
pathological conditions. Many miRNAs are expressed in
a tissue-specific or developmental-stage-specific manner,
thereby contributing greatly to cell-type-specific profiles
of protein expression [4,5]. Growing evidence suggests
that miRNAs can be regulated extensively at the levels of
promoter transcription, methylation, miRNA processing,
RNA editing, and miRNA-target interactions [6]. Tran-
scriptional regulation by nuclear receptors is the primary
level of control for miRNA expression (Table 1). Elucida-
tion of the underlying mechanisms is crucial
to understanding the pathways governing the miRNA
network [7].
1.1 microRNA
miRNAs comprise a class of short (approximately 19-24
nucleotides) single-stranded non-coding RNAs that regu-
late gene expression throughp o s t - t r a n s c r i p t i o n a l
mechanisms [8]. Since the discovery of RNA interference
(RNAi) in 1993, efforts to identify endogenous small
RNAs have led to the discovery of thousands of miRNAs
in different species [9,10]. The newest database contains
16772 entries representing hairpin precursor miRNAs
and expressing 19724 mature miRNA products in 153
species http://www.mirbase.org. Most of the miRNAs
are conserved in closely related species and many
have homologs in distant species, suggesting that their
functions could also be conserved [11]. Accumulating
evidence indicates that miRNAs play a central role in
controlling a broad range of biological activities including
embryonic development, cell proliferation, metabolic
homeostasis, and apoptosis [12]. According to their loca-
tions in the genome, miRNA genes are classified into
intragenic and intergenic regions. Although some intro-
nic miRNAs are reported to have their own promoters, a
significant percentage of miRNAs are embedded within
introns or exons of protein coding genes and share the
same transcriptional control of the host gene [13].
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host transcripts into the direct substrate of Dicer [14-16].
The biogenesis of miRNA starting in the nucleus is
found to be quite complex, involving a vast group of pro-
tein complexes [17]. In general, miRNA genes are tran-
scribed by Polymerase II as primary-miRNAs (pri-miRs).
These large RNA precursors, which are several hundred
base pairs in length, are often capped, spliced, and polya-
denylated, and can encode sequences for multiple
miRNA genes [6]. These precursors are processed by the
RNAse-III-type endonuclease Drosha in association with
the DiGeorge syndrome critical region gene 8 (DGCR8)
(or Pasha in Drosophila, PASH-1 in Caenorhabditis ele-
gans) into hairpin-shaped stem-loop structures of
approximately 60-70 nt named pre-miRNAs. The pre-
miRNAs are then exported out of the nucleus to the
cytoplasm by Expertin-5, a Ran-GFP dependent transpor-
ter that specifically recognizes dsRNAs. In the cytoplasm,
the pre-miRNAs undergo further processing by a second
RNase III enzyme, named Dicer, into a miRNA-miRNA*
duplex of variable length (~18-25 nt). Only one strand of
the miRNA duplex, designated as the “guide” strand, is
preferentially loaded into a large multi-protein miRNA
ribonucleoprotein complex (miRNP, also referred to as
the miRISC complex), and is used to modulate target
gene expression. The “passenger” strand of the miRNA-
miRNA* duplex (referred to as miRNA*) is excluded
from the miRNP complex and degraded.
The well-known “seed” region, positions 2-8 nt from the
5’miRNA, is extremely important for miRNA targeting
[18,19]. Depending on the degree of complementarity to
the target mRNA, the mechanism of silencing target
mRNA expression will be one of the following: 1) if there
is perfect complementarity to a target mRNA, there will
be target mRNA cleavage; and 2) in the case of incomplete
complementarity, translational repression or alteration of
Table 1 miRNAs regulated by NRs
miRNA
name
Regulation note target Ref.
Let 7
family
ER;PPAR;PR induced by estradiol; PPARa and PR agonist regulate let-7c. K-ras; HMGA2; caspase-3; c-
Myc; PGRMC1
[28,51,57,88-94]
miR-17-92
cluster
ER c-Myc, adiol, binds induced by estr to the miR-
17-92 promoter; p53 and STAT3 bind to the miR-17-92 promoter.
Myc;E2F;HNF1;PTEN;B
IM;ER;AIB1;cyclin D1
[30,88,95,96]
miR-21 ER;AR STAT3, NF-B, CREB and CBP/p300, ER and AR bind to the miR-21
promoter.
Pdcd4;PTEN;PPARa; [28,97-101]
miR-221/
222
ER;AR NF-B, c-JUN, ER and AR bind to the miR-221/222 promoter. P27kip1;PTEN;ERa;PUM A [29,45,102-106]
miR-200
family
ER;AR;PR upregulated by estradiol, androgen and progesterone. ZEB1; ZEB2; BMI1 [38,50,107]
miR-146a ER;AR repressed by estradiol, androgen and LPS; LPS induces NF-B binding to
the miR-416a promoter.
ROCK1; TRAF6; IRAK1; BRCA1;
CD40L; STAT1
[39,108-112]
miR-26a ER;AR Estradiol induces miR-26a, which reduces PR mRNA level EZH2;MTDH [113,114]
miR-101 AR ARE identified in the miR-101 promoter EZH2; MAGI-2; MKP-1;
ATP5B; COX-2; MYCN
[41,115-120]
miR-125b AR AR loading to the 5’ UTR region MUC1; PIGF; IGF-II; FGFR2; P53;
PUMA;E2F3
[121-126]
miR-122 HNF4a HNF4a binds to the miR-122 promoter. Hfe; Hjv; CPEB; HCV;
CAT-1; Smarcd1/Baf60a
[55,127-131]
miR-29a FXR FXR-responsive element in the miR-29a promoter; regulated by TGF-b,c -
Myc, Hedgehog or NF- B
Ski; MCT1; PTEN; CDK6 [62,63,132-135]
miR-210 RARa/
RXRa
RARa/RXRa heterodimers bind to the miR-210 promoter FGFRL1; HOXA3; E2F3; RAD52 [70,136-138]
miR-23a/
24-2
RARa/
RXRa
RARa/RXRa heterodimers bind to the miR-23a/24-2 promoter Runx2; XIAP; IL6R [70,139-141]
miR-9 TLX TLX binds to the downstream of miR-9 and miR-9 targets TLX mRNA to
form a feedback loop
PDGFR-b; Nr2e1; FoxP1; Gsh2;
NFB1
[72,142-145]
miR-34a FXR;SHP p53 binds to the miR-34a promoter; FXR interacts with p53 through SHP
to regulate miR-34a
FoxP1; Bcl-2;CDK4;E2F3;
N-MYC;SIRT1;HMGA2
[59,146,147]
miR-433/
127
SHP SHP inhibits ERRg which binds to the miR-433/127 promoters HDAC6;BCL6 [80,148,149]
miR-206 SHP SHP represses ERRg leading to decreased YY1 which inhibits AP1
activation of the miR-206 promoter
Notch3; HDAC4; KLF4; Pax7 [81,82,150-153]
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is based on the degree of seed region match with the
3’UTR of target genes. Furthermore, other “non-canonical”
miRNA-mediated mechanisms of mRNA expression mod-
ulation are emerging [21-23]. Some miRNAs can bind to
the open reading frame or 5’UTR of target genes; more-
over, they have been shown to activate, rather than to
inhibit, gene expression [21,24,25].
1.2 microRNA regulation by nuclear receptors
1.2.1 Nuclear receptors
Nuclear receptors (NRs) are ligand-activated transcrip-
tion factors that regulate the expression of target genes
by binding to cis-acting DNA sequences. The superfamily
of nuclear receptors contains 48 human members that
include classical receptors, adopted orphan receptors and
orphan receptors. Classical receptors are regulated by an
extensively studied group of endocrine ligands, such as
the estrogen receptor (ER), androgen receptor (AR), pro-
gesterone receptor (PR), and glucocorticoid receptor
(GR). Orphan nuclear receptors, like small heterodimer
p a r t n e r( S H P ) ,h a v en on a t u r a ll i g a n d s ,a n dt h e yb e h a v e
like normal transcription factors. In the past few years, a
class of so-called “adopted” orphan receptors (for which
either natural or synthetic ligands have been identified)
has arisen, such as peroxisome proliferator-activated
receptors (PPARs) and liver × receptors (LXRs). A typical
nuclear receptor usually contains five functional regions:
the A/B region that contains an N-terminal activation
function-1 (AF1) domain, the central C region that con-
tains a DNA-binding domain (DBD), the C terminal E
region that contains a ligand-binding domain (LBD) and
activation function-2 (AF-2) domain, and the D hinge
region that links the DBD to the LBD. Interestingly, the
nuclear receptors Dax-1 and SHP only have LBDs, but
they can interact with other transcription factors and
function as corepressors in regulating their target genes.
Nuclear receptors can activate or repress target genes by
binding directly to DNA response elements as homo- or
heterodimers, or by binding to other classes of DNA-
bound transcription factors. Two groups of regulators,
coactivators and corepressors, are recruited by NRs and
in turn regulate the expression of downstream target
genes.
1.2.2 Estrogen receptor (ER)
Since miRNAs are encoded by genes that are mainly
transcribed by RNA polymerase II, their transcription
can be regulated by a variety of transcription factors
including NRs [26]. After estrogenic activation, ERs med-
iate transcription by interacting directly with specific
estrogen response elements (EREs) located in the promo-
ter/enhancer region of target genes, followed by
recruitment of additional cofactors that have either acti-
vator or repressor functions on target genes [27]. For
example, ERa binds directly to the promoter region of
miR-221/222 and recruits NCoR and SMRT to suppress
miR-221/222 expression [28]. The miR-221/222 may play
a role in tamoxifen resistance because they have high
expression levels in tamoxifen resistant breast cancer. In
addition, c-Myc, induced by estrogen, can bind to the
miR-17-92 locus in an estrogen-dependent manner [29].
E2 induces the expression of let-7 family members, as
well as other miRNAs including miR-98 and miR-21,
which reduce the levels of c-Myc and E2F2 proteins [30].
Apart from regulating the expression of miRNAs at the
transcriptional level, ERa appears to be able to regulate
the biogenesis of miRNAs. Drosha is directly inhibited by
ERa [31]. Exportin 5, which controls the translocation of
precursors, is induced by estradiol and progestins [32].
The expression levels of Dicer are induced by estradiol
and progestins and are higher in ERa positive versus
negative breast cancers [33,34]. Ago2, a component of
RISC, is induced by estradiol. Ago1 and Ago2 are low in
ERa positive breast cancers [33].
1.2.3 Androgen receptor (AR)
AR is a ligand-dependent transcription factor that regu-
lates the expression of androgen target genes. Several miR-
NAs have been implicated in prostate cancer (CaP)
development, including miR-125b [35], miR-21, miR-10a,
miR-141, miR-150*, and miR-1225-5p [36,37], miR-205
and miR-200c [38], miR-146a [39], miR-221 and miR-222
[40], miR-101 and miR-26a [41], and the miR-15a-miR-
16-1 locus [42]. Transfection of synthetic miR-125b, miR-
21 or miR-141 stimulates androgen-independent growth
of CaP cells [43], while miR-146a markedly reduces cell
proliferation, invasion, and metastasis [39]. The expression
of miR-125b, an androgen induced miRNA, is high in
malignant prostate tissues. The miR-15a/miR-16-1 locus
was homozygously deleted in a subset of prostate cancers
leading to the abolishment of miR-15a, but not miR-16,
expression [42]. The recruitment of AR to the 5’DNA
region of miR-125b and miR-21 has been confirmed by
ChIP analysis [37,43].
ARs can also bind to the promoter region of miR-221 to
repress miR-221 expression in LNCaP cells [44]. Knock-
ing-down miR-221 increases LNCaP cell migration and
invasion by targeting DVL2 [45]. The circulating level of
miR-21, miR-141 and miR-221 in the bloodstream might
be useful as a prognostic marker in patients with prostate
cancer [46,47]. miR-616 is over-expressed specifically in
malignant prostate tissues, not in benign prostate speci-
mens. Stable miR-616 overexpression in LNCaP cells sti-
mulates prostate cancer cell proliferation and castration
resistance [48].
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In mammalian pregnancy, uterine quiescence is main-
tained by elevated circulating progesterone (P4) acting
via PR. The miR-200 family, including miR-200b/c/429
and miR-200a/141, is upregulated during late gestation
and labor [49]. P4 injection causes a modest decrease in
myometrial expression of miR-200b/429, yet it also sig-
nificantly increases ZEB1 mRNA and protein, a target of
the miR-200 family. Further studies show that ZEB2
rather than ZEB1 is acting as a transcriptional repressor
on the miR-200c/141 promoter [50]. In SKOV-3 cells,
the expression of let-7, which targets PGRMC1 (proges-
terone receptor membrane component 1), is increased
after stimulation with progesterone [51]. Progesterone is
also reported to regulate miR-320 expression [52]. Con-
versely, miR-126-3p inhibits PR protein expression as
well as the proliferation of mammary epithelial cells by
targeting the PR 3’UTR directly [53].
1.2.5 Hepatocyte nuclear factor-4a (HNF4a)
HNF-4a is a highly conserved nuclear receptor that is
expressed in the liver, kidney, intestine, and pancreas.
HNF-4a is a key regulator of energy metabolism, glucose
and lipid homeostasis [54]. A putative binding site for
HNF-4a is found in the conserved core element of the
hpri-miR-122 promoter. The miR-122 promoter activation
by HNF-4a is further enhanced by the addition of PGC1a,
a well-recognized co-activator of HNF4a [55].
1.2.6 Peroxisome proliferator-activated receptor (PPAR)
MiR-29a and 29c levels are decreased in the rat heart after
7-day treatment with PIO, a peroxisome proliferator-acti-
vated receptor (PPAR)-g agonist [56]. Wy-14,643, a speci-
fic PPARa agonist, inhibits microRNA let-7c expression
via a PPARa-dependent pathway. The lack of any signifi-
cant difference in basal let-7c expression between the WT
and PPARa-null mice suggests an active transrepression
mechanism, where the receptor is recruited to the geno-
mic regulatory region of let-7c following ligand treatment
[57]. Because let-7c targets the c-Myc 3’UTR for degrada-
tion, the PPARa-mediated induction of c-Myc via let-7c
subsequently increases the expression of oncogenic miR-
17-92 clusters [58].
1.2.7 Farnesoid × receptor (FXR)
FXR is the primary biosensor for endogenous bile acids
and regulates the expression of numerous genes involved
in lipid and glucose metabolism. miRNAs regulated by
FXR were detected by miRNA microarray analysis with
hepatic RNAs of wild type or FXR-null mice. Of the miR-
NAs tested, the level of miR-34a is upregulated in FXR-
null mice. The mechanism of this regulation is as follows:
activation of FXR induces SHP, which in turn suppresses
miR-34a gene transcription by inhibiting p53 binding to
the miR-34a promoter [59]. Treatment with GW4064, a
synthetic FXR ligand, upregulates miR-29a in hemato-
poietic stem cells (HSCs) isolated from wild-type mice,
rats, and humans but not from FXR-null mice. A FXR-
responsive element has been identified in the miR-29a
promoter, which is involved in the regulation of extracel-
lular matrix (ECM) production in liver [60]. The expres-
sion of miR-29a is also negatively regulated by TGF-b,
c-Myc, hedgehog or NF-B signaling in liver and lung
fibrosis [61-63].
1.2.8 Liver × receptor (LXR)
LXR plays an important role in the metabolism and
homeostasis of cholesterol, lipids, bile acids, and steroid
hormones [64]. After endogenous or synthetic ligand
binding, LXR forms a heterodimer with retinoid × recep-
tor (RXR) and binds to LXR response elements (LXREs)
in the promoters of LXR target genes. Treatment with
GW3965, a LXR ligand, induces the expression of mature
hsa-miR-613 in primary human hepatocytes as well as in
human hepatoma HepG2 and Huh7 cells. The positive
regulation of hsa-miR-613 by LXR is mediated by the
sterol regulatory element binding protein (SREBP)-1c, a
known LXR target gene [65]. Interestingly, hsa-miR-613
can target the 3’UTR of endogenous LXRa. The negative
regulation mediated by hsa-miR-613 and SREBP-1c and
t h ep r e v i o u s l yr e p o r t e dp o s i t ive regulation mediated by
an LXRE constitute a negative autoregulatory feedback
loop to ensure a tight regulation of LXRa [66].
1.2.9 Pregnane × receptor (PXR)
PXR is a crucial regulator of drug metabolism in liver and
small intestine. PXR dimerizes with RXRa and binds to
the response elements of its target genes, including
CYP3A4 [67]. Eleven out of the three hundred human
miRNAs that have been identified exhibit a more than
three-fold altered expression in HepG2 cells treated with
the PXR ligand rifampicin. MiR-31 is 5.4-fold down-regu-
lated, whereas all others, namely miR-193a -5p, miR-296-
5p, miR-324-5p, miR-379, miR-411, miR-489, miR505,
miR-519a, miR-545 and miR-548b-5p, exhibit up to 5.8-
fold higher expression levels [68,69]. Interestingly, miRNA
can regulate PXR expression too. For example, miR-148a
post-transcriptionally regulates human PXR, resulting in
the modulation of the inducible and/or constitutive levels
of CYP3A4 in human liver [67].
1.2.10 Retinoic acid receptor (RAR) and retinoic ×
receptor (RXR)
To identify potential transcription factor binding sites
(TFBS) in the promoter regions of 247 human intergenic
microRNAs (from a miRNA promoter dataset provided by
Mahony et al [70]), NHR-Scan was used for the PML-
RARA fusion protein [69]. Sixty-five microRNA promoters
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tions are focused on the miR-210 and cluster of miR23a/
24-2. After treating with the RAR agonist all-trans retinoic
acid (ATRA), expression of miR-23a and miR-210 is
increased. ChIP experiments directed against both RARa
and RXRa in 293T cells show that RARa/RXRa heterodi-
mers bind miR-210 and miR-23a/24-2 promoters. This
method which is start with prediction of NR binding site
in miRNA promoter database, is different from other
microRNA array first analysis [69].
1.2.11 Nuclear receptor TLX (homologue of the
Drosophila tailless gene)
Orphan nuclear receptor TLX, which is expressed in the
neuroepithelium of the embryonic mouse brain and in
adult neurogenic regions, is essential for neural stem cell
(NSC) proliferation [71]. TLX binds to downstream of
the miR-9 sequence at the miR-9-1 locus and represses
miR-9 at the transcriptional level. Meanwhile, miR-9 tar-
gets TLX mRNA for destabilization and/or translational
inhibition, reducing TLX protein levels. MiR-9 and TLX
thus form a feedback loop to regulate the switch of
neural stem cell proliferation and differentiation [72].
1.2.12 Small heterodimer partner (SHP)
SHP is an orphan nuclear receptor that contains the
ligand-binding domain (LBD), but lacks the DNA binding
domain (DBD) [73]. SHP functions as a transcriptional
repressor though interacting with other NRs, and plays
important roles in several metabolic diseases and in liver
carcinogenesis [74-77]. SHP interacts with ERRg to control
the expression of miR-433 and miR-127 in several mam-
malian species [78-80]. SHP also activates miR-206 expres-
sion through a ‘’dual inhibitory’’ mechanism [81], which in
miRNAs
NRs
RNAPII
Target genes or miRNAs
NRs
RNAPII
TFs or co-regulators
AAAA
Target genes
AAAA
miRISC
Drosha, 
DGCR8
Pri-miRNA Pre-miRNA
Exportin 5
Dicer
Mature miRNA
2. ER interacts 
with and 
inhibits Drosha
3. Estradiol and 
progestins induce 
expotin 5 expression
4. Estradiol and 
progestins induce 
Dicer expression
5. Ago2 is induced by 
estradiol
1. NRs bind directly to the 
promoters of miRNAs
1. NRs indirectly regulate 
miRNAs though the 
“cascade reaction”
Figure 1 Nuclear receptor regulation of miRNA expression and biogenesis. 1. The miRNA genes are transcribed by RNA polymerase II to
produce pri-miRNAs. NRs bind directly to the miRNA gene promoters or interact with other transcription factors that bind to the target miRNA
promoters. 2. The pri-miRNAs are cleaved by Drosha and DGCR8 to become pre-miRNAs, which have hairpin-shaped stem-loop structures. ERa
inhibits Drosha by direct interaction. 3. The pre-miRNAs are exported to the cytoplasm by Expertin-5 that is induced by estradiol and progestins.
4. The pre-miRNAs undergo further processing by Dicer to become mature miRNAs. The expression of Dicer is increased by estradiol and
progestins. 5. The mature miRNAs are loaded to the miRISC to regulate target gene expression. Ago2, a component of the RISC, is induced by
estradiol.
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signaling is important in controlling the expression of
miR-34a and its target SIRT1 [83].
1.2.13 Other NRs
Other members of the NR family are also involved in
miRNA expression regulation. Glucocorticoids (GC) bind
to both the glucocorticoid receptor (GR) and mineralo-
corticoid (MR). Both receptor types act through transac-
tivation at glucocorticoid response elements (GREs) [84].
GR controls a variety of physiological functions, such as
metabolism, development, and reproduction; whereas
MR is critical for controlling sodium and potassium
transport, pathophysiology of hypertension, and cardiac
fibrosis [85]. Several miRNAs/mirtrons are regulated by
GC in patients and cell lines, including the myeloid-
specific miR-223 and the apoptosis and cell cycle arrest-
inducing miR-15/16 clusters. miR-15b/16 increases GC
sensitivity in leukemia cell lines, further suggesting that
miRNA regulation is a vital component of GC signaling
[86]. In addition, miR-208 potentiates bMHC expression
through a mechanism involving the thyroid hormone
receptor [87].
1.3 Conclusion
NRs appear to regulate miRNA expression via three
means: direct binding to the promoter regions of miRNAs,
indirect regulation of miRNA expression through NR tar-
get genes, and involvement in regulation of miRNA bio-
genesis (Figure 1). Microarray analyses has revealed large
numbers of miRNAs that are differentially regulated by
NRs or their ligands, but the detailed regulatory mechan-
isms remain to be elucidated. Future exploration of the
interactions between NRs and miRNAs in the regulation
of gene expression networks is needed for better under-
standing of miRNA modulation and function by NR
signaling.
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